Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
69
About the Report
About the Report
Summary
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS); and for the management of spasticity; and neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.
Acorda Therapeutics Inc (ACOR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Acorda Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For USD 13 Million 13
Venture Financing 15
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises USD 38 Million In Series B Venture Financing 17
Private Equity 19
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Equity Offering 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For USD 25 Million 28
Debt Offering 29
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Asset Transactions 33
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Acquisition 34
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 39
Acorda Therapeutics Inc-Key Competitors 40
Acorda Therapeutics Inc-Key Employees 41
Acorda Therapeutics Inc-Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 44
Strategy And Business Planning 44
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 44
Financial Announcements 45
Oct 31, 2018: Acorda provides financial and pipeline update for third quarter 2018 45
Aug 02, 2018: Acorda provides financial and pipeline update for second quarter 2018 47
May 02, 2018: Acorda Provides Financial and Pipeline Update for First Quarter 2018 48
Feb 15, 2018: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017 50
Jan 08, 2018: Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference 52
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 54
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 56
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 58
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 60
Corporate Communications 62
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 62
Product News 63
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 63
Clinical Trials 64
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 64
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 65
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 67
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69
List of Figure
List of Figures
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For USD 13 Million 13
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises USD 38 Million In Series B Venture Financing 17
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For USD 25 Million 28
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For USD 13 Million 39
Acorda Therapeutics Inc, Key Competitors 40
Acorda Therapeutics Inc, Key Employees 41
Acorda Therapeutics Inc, Subsidiaries 42
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.